4854-7660-7496 v.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 1 COMMERCIAL MANUFACTURING SERVICES AGREEMENT THIS COMMERCIAL MANUFACTURING SERVICES AGREEMENT is made as of May 22nd, 2026 (the “Effective Date”) by and between WuXi Biologics (Hong Kong) Limited, a corporation organized under the laws of Hong Kong, with its registered address at Unit 417, 4th Floor, Lippo Centre Tower Two, No. 89 Queensway, Admiralty, Hong Kong (“WuXi Biologics”), and Viridian Therapeutics, Inc., a Delaware corporation having its principal place of business at 221 Crescent Street, Suite 103A, Waltham, MA 02453 (“Client”). WuXi Biologics and Client may be referred to herein as a “Party” or, collectively, as “Parties.” RECITALS WHEREAS, Client and its Affiliates are engaged in the discovery, development, manufacture and sale of biopharmaceutical products; WHEREAS, WuXi Biologics has the requisite infrastructure, licenses, permits and capabil

…

EXECUTION VERSION

IMMUNOVANT, INC.

2019 EQUITY INCENTIVE PLAN

CAPPED VALUE APPRECIATION RIGHT AWARD GRANT NOTICE

| | | | | | |

…

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKEDBY [***], HAS BEEN OMITTED BECAUSE ROIVANT SCIENCES LTD. (THE “COMPANY”)HAS DETERMINED THAT THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULDLIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

ROIVANT SCIENCES, INC.

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

This Amended and Restated Employment Agreement (this “Agreement”) is entered into by and between Frank Torti (the “Executive”)and Roivant Sciences, Inc. (the “Company”) and is effective as of July 28, 2025 (the “Effective Date”).This Agreement hereby amends and restates, as of the Effective Date, Executive’s prior employment agreement with the Company dated July 20, 2018, as amended and restated as of August 20, 2020 (the “Prior Agreement”), and supersedes any and all prior and contemporaneous oral or written employment agreements or arrangements, including the Prior Agreement, between the Executive and the Company or any predecessor thereof.

RECITALS

…

PRECISION BIOSCIENCES, INC. AMENDMENT TO EXTEND CONSULTING AGREEMENT

This amendment (this “Amendment”), dated and effective as of June 29, 2026 (the “Amendment Effective Date”), is entered into by and between Dr. Stanley R. Frankel, MD (the “Independent Contractor”) and Precision BioSciences, Inc. (“Company”).

WHEREAS, the Independent Contractor and Company have entered into a Consulting Agreement dated June 23, 2025 (the “Agreement”); and

WHEREAS, the parties wish to amend the Agreement to extend its term, pursuant to Section 11(A) and Section 21 of the Agreement and as set forth herein.

NOW, THEREFORE, the parties hereto agree as follows:

1.DEFINITIONS. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Agreement.

…

Execution Version

FIRST AMENDMENT TO LOAN AGREEMENT

This First Amendment to Loan Agreement (this “Amendment”), dated as of April 28, 2026, is made and entered into by and between REGENXBIO RS LLC, a Delaware limited liability company, as borrower (“Borrower”) and HCR RGNX ROYALTY SPV, LP, a Delaware limited partnership (“Lender”) (each a “Party” and collectively the “Parties”).

WHEREAS, the Parties entered into that certain Loan Agreement dated as of May 16, 2025 (the “Agreement”; capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement) pursuant to which the Lender has extended credit to the Borrower on the terms set forth therein; and

WHEREAS, the Parties wish to clarify the interest payment mechanics under the Agreement.

NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable consideration, the adequacy and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

1.

…

Execution Version

FOURTH AMENDMENT TO CREDIT AGREEMENT

This FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Agreement”), is entered into as of July 23, 2026, by and among ACUREN DELAWARE HOLDCO, INC., a Delaware corporation (the “Initial Borrower”), ACUREN HOLDINGS, INC., a Delaware corporation (“Acuren” and together with the Initial Borrower, the “Borrowers”), TIC SOLUTIONS, INC., a Delaware corporation (“Holdings”), the other Loan Parties party hereto, the Revolving Credit Lenders party hereto, the L/C Issuers party hereto and JEFFERIES FINANCE LLC, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”). All capitalized terms used herein (including in this preamble) and not otherwise defined herein shall have the respective meanings provided such terms in the Credit Agreement or the Amended Credit Agreement, as applicable (each as defined below).

W I T N E S S E T H:

…

EXECUTIVE EMPLOYMENT AGREEMENT

THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made as of the 7th day of May 2026 (the “Effective Date”) by and between TIC Solutions, Inc. (“Company”) and Jennifer Phan (“Executive”).

WHEREAS, the Company desires to employ the Executive as its Chief Legal Officer and Secretary and Executive desires to accept such employment under the terms and conditions hereof.

NOW, THEREFORE, in consideration of the promises and the mutual agreements contained herein, the Company and Executive each hereby agree as follows:

ARTICLE I DEFINITIONS

1.1    Definitions. As used herein, the following terms shall have the following meanings.

(a)    “Benefit Continuation” means the continued participation for Executive and her eligible dependents in the Company Group’s medical and dental benefit plans, via an effective election by Executive under COBRA.

…

SUCCESS BONUS AGREEMENT

This SUCCESS BONUS AGREEMENT (the “Agreement”) is made and entered into this May 14, 2026, by and between Vistance Networks Holdings, LLC (the “Company”), and Bartolomeo Giordano (“Employee”). For purposes of this Agreement, the Company and Employee are referred to collectively as the “Parties.”

RECITALS

Pursuant to the Purchase Agreement by and between Vistance Networks, Inc. (“VISN”) and Belden Inc. (“Belden”), dated as of April 29, 2026 (the “Purchase Agreement”), Belden has agreed to buy, and VISN has agreed to sell, the Company’s Ruckus business (the “Transaction”).

In order to recognize Employee’s valuable leadership and contributions to the success of the Company, and to encourage Employee’s continued commitment, dedication, and services leading up to the Transaction, the Company wishes to provide an incentive to encourage Employee to remain actively employed by the Company through the consummation of the Transaction (the “Closing”).

…

CONSULTING AGREEMENT

THIS CONSULTING AGREEMENT(together with the attached Exhibit A(the “Business Terms Exhibit”) and Exhibit B(the “Data Privacy Exhibit”), the “Agreement”), is effective as of April 9, 2026 (the “Effective Date”) by and between Korro Bio, Inc., a Delaware corporation with a principal business address at 60 First Street, 2ndFloor, Suite 250, Cambridge, MA 02141 (“Korro”), and Rachel Meyers, Ph.D. with an address at [Address omitted] (“Consultant”). Korro desires to have the benefit of Consultant’s knowledge and experience, and Consultant desires to provide services to Korro, all as provided in this Agreement.

1.

Services.Korro retains Consultant, and Consultant agrees to provide, consulting and advisory services to Korro as Korro may from time to time reasonably request and as specified in the Business Terms Exhibit(the “Consulting Services”). Any changes to the Consulting Services (and any related compensation adjustments) must be agreed to in writing between Consultant and Korro prior to implementation of the changes.

2.

…

KORRO BIO, INC.

2026 INDUCEMENT PLAN

SECTION 1.

GENERAL PURPOSE OF THE PLAN; DEFINITIONS

The name of the plan is the Korro Bio, Inc. 2026 Inducement Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to enable Korro Bio, Inc. (the “Company”) and its Affiliates to grant equity awards to induce highly-qualified prospective officers and employees who are Eligible Employees to accept employment and to provide them with a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company. The Company intends that the Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Marketplace Rules of The Nasdaq Stock Market LLC (“Nasdaq”).

The following terms shall be defined as set forth below:

…

KORRO BIO, INC.

AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Korro Bio, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (“Outside Directors”). This Policy will become effective as of April 8, 2026 (the “Effective Date”). In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as set forth below:

I.

Cash Retainers

Annual Retainer for Board Membership: $40,000 for general availability and participation in meetings and conference calls of our Board of Directors, to be paid quarterly in arrears, pro-rated based on the number of actual days served by the director during such calendar quarter. No additional compensation for attending individual Board of Directors meetings.

…

CARTESIAN THERAPEUTICS, INC. AMENDED AND RESTATED 2018 EMPLOYMENTINDUCEMENT INCENTIVE AWARD PLAN

ARTICLE I.
PURPOSE

The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI.

ARTICLE II.
ELIGIBILITY

Eligible Individuals are eligible to be granted Awards under the Plan, subject to the limitations described herein.

ARTICLE III.
ADMINISTRATION AND DELEGATION

…